Hematological malignancy Lymphoma, leukemia, hematological malignancy
Conditions
Interventions
HLA-haploidentical related hematopoietic stem cell transplantation with myeloablative conditioning using fludarabine 125 mg/m2, buslfan 12.8 mg/kg and cyclophosphamide 29 mg/kg, and GVHD prophylaxis u
Sponsors
Okamura Atsuo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Hematopoietic malignant tumors suitable for hematopoietic stem cell transplantation 2. Disease status; remission phase or non-remission phase 3. Age; >=16 year-old, =50% b. T-Bil = 30ml/min d. SpO2 >=95% (room air) 6. No HLA-matched related donor 7. No HLA-matched unrelated donor 8. Written informed consent
Exclusion criteria
Exclusion criteria: 1.HIV antibody positivity 2.Active multiple primary cancers 3.Active infection 4.Pregnant, unwilling to practice contraception during the study, or lactating female 5.Hypersensitivity to agents used for conditioning and GVHD prophylaxis 6.Specific HLA antibody against donor HLA 7.Administration of anticancer drugs except the study protocol within 13 days before transplantation 8. Other, determination of the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One-year survival rate following transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| Graft survival rate, incidence rate and severity of acute/chronic GVHD, incidence rate of infection, GVHD free/relapse free survival, discontinuance rate of immune-suppressive agents, Fever during day 0 and day7, adverse events | — |
Contacts
Public ContactAtsuo Okamura
Kakogawa Central City Hospital
Outcome results
None listed